SCN5A Variant Y159C
Summary of observed carriers, functional annotations, and structural context for SCN5A Y159C. Data combine curated literature, international cohorts, and gnomAD observations.
Estimated LQT3 penetrance
0%
0/16 effective observations
Estimated BrS1 penetrance
15%
2/16 effective observations
Total carriers
6
0 BrS1 · 0 LQT3 · 6 unaffected
Variant features alone are equivalent to phenotyping 2 individuals for Brugada syndrome and 0 individuals for LQT3.
In silico predictors
| PROVEAN | PolyPhen-2 | BLAST-PSSM | REVEL | Penetrance Density BrS (%) | Penetrance Density LQT3 (%) |
|---|---|---|---|---|---|
| -2.77 | 1 | -1.68 | 0.886 | 24 | 0 |
PROVEAN scores below -2 suggest deleterious impact. REVEL scores above 0.5–0.75 are often interpreted as likely pathogenic. PolyPhen-2 scores above 0.85 are typically pathogenic. Penetrance density summarises neighbouring residue risk (Kroncke et al. 2019).
Reported carrier data
| Source | Year | Carriers | Unaffected | LQT3 | BrS1 | Other | Other Disease |
|---|---|---|---|---|---|---|---|
| Literature, cohort, and gnomAD | – | 6 | 6 | 0 | 0 | – | |
| Variant features alone | – | 15 | 13 | 0 | 2 | – | – |
Totals may differ from individual publications due to duplicate patients removed during curation.
Nearby variants
Neighbouring residues within 15 Ångström provide structural context. Variants listed in the right-most column have been observed clinically or in gnomAD.
| Neighbour residue | Distance (Å) | Observed variants |
|---|---|---|
| 208 | 13 | E208K |
| 154 | 14 | P154L, |
| 156 | 10 | W156R, W156R, W156X, |
| 168 | 15 | |
| 158 | 7 | K158T, |
| 163 | 7 | c.486delC, |
| 166 | 12 | A166T, |
| 167 | 13 | |
| 161 | 7 | E161K, E161Q, |
| 144 | 13 | |
| 151 | 13 | |
| 146 | 15 | V146M, V146A, |
| 159 | 0 | Y159C, Y159X, |
| 153 | 15 | |
| 155 | 10 | |
| 147 | 10 | |
| 150 | 13 | |
| 164 | 9 | F164L, F164L, F164L, |
| 157 | 5 | T157I, |
| 143 | 13 | |
| 148 | 15 | |
| 160 | 4 | p.V160fs, |
| 165 | 11 | |
| 140 | 14 | |
| 162 | 7 | Y162H, Y162C, |